Literature DB >> 6661375

Pharmacokinetics of brotizolam in the elderly.

R Jochemsen, K L Nandi, D Corless, J G Wesselman, D D Breimer.   

Abstract

Disposition of brotizolam in patients aged 71-93 years was compared with that of healthy young subjects aged 21-26 years. The mean elimination half-life of brotizolam was about twice as long in the elderly as in the young subjects: 9.3 (4.0-19.5) h and 4.8 (3.1-6.3) h respectively. Increase in elimination half-life was attributable to a decrease in hepatic clearance, i.e. 40 (20-58) ml/min in the elderly and 109 (77-156) ml/min in the young. Volume of distribution and protein binding were the same with mean values of 0.56 (0.45-0.72) l/kg and 9.0 (6.8-11.9) % in the elderly and 0.63 (0.40-0.77) l/kg and 8.4 (7.5-9.4) % in the young. Absorption rate of brotizolam was relatively slow in the elderly with a mean peak time of 1.7 h compared with 1.1 h in the young. Mean bioavailability was almost 70% for both groups. Normalized for body weight and dose (0.25 mg) mean peak concentrations were 247 (137-395) ng ml-1 kg in the young and 343 (251-446) ng ml-1 kg in the elderly. It is unlikely that substantial drug accumulation will occur if elderly patients ingest 0.25 mg brotizolam nightly.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661375      PMCID: PMC1428236          DOI: 10.1111/j.1365-2125.1983.tb02304.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Effects of aging and liver disease on disposition of lorazepam.

Authors:  J W Kraus; P V Desmond; J P Marshall; R F Johnson; S Schenker; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1978-10       Impact factor: 6.875

2.  Altered elimination of desmethyldiazepam in the elderly.

Authors:  U Klotz; P Müller-Seydlitz
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

Review 3.  Drug use in the elderly: a review of problems and special considerations.

Authors:  R E Vestal
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

4.  Classification and bioavailability studies with WE 941 by quantitative pharmaco-EEG and clinical analyses.

Authors:  B Saletu; J Grünberger; J Volavka; P Berner
Journal:  Arzneimittelforschung       Date:  1979

5.  Lorazepam kinetics in the elderly.

Authors:  D J Greenblatt; M D Allen; A Locniskar; J S Harmatz; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

6.  The effects of age and liver disease on the disposition and elimination of diazepam in adult man.

Authors:  U Klotz; G R Avant; A Hoyumpa; S Schenker; G R Wilkinson
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

7.  Human pharmacokinetics of nitrazepam: effect of age and diseases.

Authors:  L Kangas; E Iisalo; J Kanto; V Lehtinen; S Pynnönen; I Ruikka; J Salminen; M Sillanpää; E Syvälahti
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

Review 8.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Normal disposition of oxazepam in acute viral hepatitis and cirrhosis.

Authors:  H J Shull; G R Wilkinson; R Johnson; S Schenker
Journal:  Ann Intern Med       Date:  1976-04       Impact factor: 25.391

10.  Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium).

Authors:  R K Roberts; G R Wilkinson; R A Branch; S Schenker
Journal:  Gastroenterology       Date:  1978-09       Impact factor: 22.682

View more
  10 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 3.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

4.  Pharmacokinetics of oral brotizolam in patients with liver cirrhosis.

Authors:  R Jochemsen; R P Joeres; J G Wesselman; E Richter; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

5.  Research in the Division of Pharmacology.

Authors:  D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1985-04-26

6.  Safety of brotizolam in hospitalized patients.

Authors:  Ophir Lavon; Shmuel Bejel
Journal:  Eur J Clin Pharmacol       Date:  2018-03-22       Impact factor: 2.953

7.  Elimination of brotizolam in elderly patients after multiple doses.

Authors:  W D Bechtel; E Goetzke
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic.

Authors:  M S Langley; S P Clissold
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

9.  Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing.

Authors:  P D Kroboth; J W McAuley; R B Smith
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

10.  Kinetic and dynamic interaction of brotizolam and ethanol.

Authors:  J M Scavone; D J Greenblatt; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.